Background
This case concerns a dispute between Tyonex Nigeria Limited (the appellants) and Pfizer Limited (the respondent) regarding the alleged infringement of patent rights related to a pharmaceutical product. Pfizer claimed ownership of the product 'Norvasc', registered under Nigerian patent law, and asserted that Tyonex’s product, branded 'Amlovas', infringes upon this patent. After Pfizer raised concerns, the National Agency for Food and Drug Administration and Control (NAFDAC) deregistered Amlovas. Despite this, Tyonex allegedly persisted in its importation and sales. Pfizer subsequently launched a lawsuit in the Federal High Court, seeking injunctions against Tyonex, damages for the infringement, and further action against the distribution of Amlovas.
Issues
The Supreme Court was faced with crucial legal questions, particularly:
- Whether the lower court properly handled the issues raised in the trial, especially concerning the appellants' right to fair hearing.
- Whether the trial court’s decision, based on evidence that was not subjected to cross-examination, constituted a miscarriage of justice.
Ratio Decidendi
The Supreme Court found substantial flaws in the proceedings of the lower court which led to a violation of the appellants' right to fair hearing. It underscored that a witness's absence for cross-examination, notably an expert witness whose evidence heavily influenced the outcome, fundamentally compromised the integrity of the trial.
Court Findings
The court established that:
- The trial court relied on evidence from Professor George Barany, who did not present for cross-examination. This was deemed a significant procedural error.
- The failure to allow cross-examination effectively denied Tyonex the opportunity to challenge the validity of the deposition, leading to a substantial miscarriage of justice.
- The counterclaim raised by Tyonex was improperly dismissed without adequate consideration, which further necessitated a retrial.
Conclusion
The Supreme Court determined that the proceedings from the lower court were fundamentally flawed due to multiple violations of procedural justice, particularly regarding fair hearing rights. It concluded that the matter should be remitted to the Federal High Court for a full and fair retrial with all issues duly addressed.
Significance
This ruling emphasizes the crucial role of the right to fair hearing within judicial proceedings, particularly in cases involving expert testimonies. It also highlights the necessity for trial judges to ensure that all relevant evidence is subject to scrutiny through cross-examination. This decision reinforces protections against potential abuses in patent law disputes and aims to uphold the integrity of the judicial process.